Alpha 2.0
Login Register
» Authors » T Peretz-Yablonski

T Peretz-Yablonski

Explore the profile of T Peretz-Yablonski including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 3
Citations 86
Followers 0
Related Specialty
Oncology
Top 10 Co-Authors
F Puglisi
S Paluch-Shimon
I Bondarenko
Y du Toit
T Bachelot
J-L Merot
D Miles
A Wardley
A Schneeweiss
E Ciruelos
Published In
Ann Oncol
ESMO Open
Affiliations
Soon will be listed here.
Recent Articles
1.
Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer
Condorelli M, Bruzzone M, Ceppi M, Ferrari A, Grinshpun A, Hamy A, et al.
ESMO Open . 2021 Nov; 6(6):100300. PMID: 34775302
Background: Knowledge is growing on the safety of assisted reproductive techniques (ART) in cancer survivors. No data exist, however, for the specific population of breast cancer patients harboring germline BRCA1/2...
2.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, et al.
Ann Oncol . 2021 Jul; 32(10):1245-1255. PMID: 34224826
Background: The phase III CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) trial established the combination of pertuzumab, trastuzumab and docetaxel as standard first-line therapy for human epidermal growth factor receptor...
3.
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, et al.
Ann Oncol . 2019 Feb; 30(5):766-773. PMID: 30796821
Background: Pertuzumab combined with trastuzumab and docetaxel is the standard first-line therapy for HER2-positive metastatic breast cancer, based on results from the phase III CLEOPATRA trial. PERUSE was designed to...